CBD superbugs — New research presented at the annual meeting of the American Society of Microbiology has shown that a new topical formation containing cannabidiol (CBD) is effective in killing (superbugs) bacterial infections in the skin. It was also found that the formulation kills certain bacteria resistant to antibiotics.
We have long known that certain cannabinoids found in marijuana have impressive antibacterial properties. Of course, that does not mean that these compounds are immediately converted into effective antibiotics. For example, it has been discovered that smoking marijuana potentially reduces the body’s ability to fight certain bacterial infections (superbugs).
Botanix Pharmaceuticals has been working to harness the antibacterial potential of the CBD by creating an effective delivery system to treat a variety of skin conditions. The details of the latest formulation of the company, called BTX 1801, have been presented by the University of Queensland researcher Mark Blaskovich at the annual conference of the American Society of Microbiology in San Francisco.
The new data revealed that the CBD formulation is effective in killing a number of bacteria, including several strains resistant to antibiotics. The research suggests that the BTX 1801 kills the bacteria quickly, in just a few hours, while the continuous treatments also revealed that the bacterium did not develop resistance against the new formulation of CBD.
It is important to note that this new research has not been reviewed by experts or published in a journal, but has only been demonstrated in laboratory conditions and animal models, so we must continue working to verify the effectiveness of human subjects. However, Botanix has several similar formulations of CBD in various stages of the human trial. The most advanced is a compound derived from the CBD called BTX 1503, which is designed to treat moderate to severe acne. This treatment yielded extraordinarily promising results in human phase 1 trials and is on track to start larger phase 2 studies this year.
The most significant limitation in the potential of CBD as an antibiotic is the fact that it seems to be only effective in killing Gram-positive bacteria and not Gram-negative bacteria. This means that the CBD may never become the magic solution against the broader increase in antibiotic-resistant bacteria, but these new innovative ways of treating specific bacterial skin infections suggest that the compound derived from marijuana still offers promising therapeutic results.
Abbreviation of the term cannabidiol, CBD is one of many cannabinoids contained in cannabis, among which is also tetrahydrocannabinol (THC). But if these molecules are close, their effects differ a lot.
Unlike THC, CBD has no “intoxicating” effect, but only relaxing properties. Since 2011, the law has allowed the marketing of cannabis products whose THC content is regulated: it must be less than 1%. In order to obtain these “legal” plants, selection is made by selective crosses, with a low THC content and a high CBD content (between 5 and 25% on average). These plants, which are indistinguishable from illegal cannabis with the naked eye or the smell, do not result in a change in perception and mood, or a “hovering” effect, as may be the case when illegal cannabis use, high in THC.
The majority of studies have focused on THC alone (often in the form of dronabinol, synthetic THC), particularly in the oncology field. Medical research is also investigating the action of cannabidiol on cancer cells, interesting observations have been made for some cancers, especially in laboratory experiments or with rodents, but not in humans.
Interesting results have been found for other diseases in which activation of the immune system is involved, such as Alzheimer’s disease, multiple sclerosis, type I and type II diabetes, Parkinson’s disease, etc. “CBD has anti-inflammatory and immunomodulatory effects. It also seems to act as a neuroprotective protecting the brain cells, “said the report of Addiction Switzerland, which nevertheless states that here too” most studies have however been conducted on animals only. It is therefore difficult to draw conclusions about the effects linked to the mere presence of the CBD “.
CBD also works against epileptic seizures in children. In cases of severe epilepsies resistant to conventional treatments, CBD makes it possible to reduce the frequency of seizures. Promising drugs are already appearing on the market.
Other studies highlight the anxiolytic properties of CBD. Even at low doses, it seems to reduce stress and anxiety. Two important effects for many psychic pathologies, but which can also be sought for the well-being they bring. However, serious clinical studies are still missing on this subject, as well as the action of CBD to treat sleep disorders.
More promising seems its antipsychotic effect, especially studied in patients with schizophrenia. Very high dosages of CBD are however necessary, which raises problems of drug interactions and cost.